The stock price of Halozyme Therapeutics Inc. (NASDAQ: HALO) has plunged by -3.98 when compared to previous closing price of 58.53, but the company has seen a -9.25% decline in its stock price over the last five trading sessions. prnewswire.com reported 2024-09-13 that OCREVUS ZUNOVO™ has the potential to expand treatment options to centers without IV infrastructure or with IV constraints SAN DIEGO, Sept. 13, 2024 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Roche received U.S. Food and Drug Administration (FDA) approval for OCREVUS ZUNOVO™ (ocrelizumab and hyaluronidase-ocsq) with Halozyme’s ENHANZE® drug delivery technology for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS) as a twice-a-year, approximately 10-minute subcutaneous (SC) injection to be administered by a healthcare practitioner.
Is It Worth Investing in Halozyme Therapeutics Inc. (NASDAQ: HALO) Right Now?
Halozyme Therapeutics Inc. (NASDAQ: HALO) has a price-to-earnings ratio that is above its average at 21.79x. The stock has a 36-month beta value of 1.28. Opinions on the stock are mixed, with 5 analysts rating it as a “buy,” 2 as “overweight,” 2 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for HALO is 125.30M, and at present, short sellers hold a 8.01% of that float. On September 25, 2024, the average trading volume of HALO was 1.29M shares.
HALO’s Market Performance
HALO’s stock has seen a -9.25% decrease for the week, with a -10.40% drop in the past month and a 7.25% gain in the past quarter. The volatility ratio for the week is 3.71%, and the volatility levels for the past 30 days are at 3.10% for Halozyme Therapeutics Inc. The simple moving average for the past 20 days is -8.33% for HALO’s stock, with a 23.60% simple moving average for the past 200 days.
Analysts’ Opinion of HALO
Many brokerage firms have already submitted their reports for HALO stocks, with JP Morgan repeating the rating for HALO by listing it as a “Neutral.” The predicted price for HALO in the upcoming period, according to JP Morgan is $57 based on the research report published on September 19, 2024 of the current year 2024.
Piper Sandler, on the other hand, stated in their research note that they expect to see HALO reach a price target of $51, previously predicting the price at $48. The rating they have provided for HALO stocks is “Neutral” according to the report published on June 07th, 2024.
TD Cowen gave a rating of “Outperform” to HALO, setting the target price at $54 in the report published on February 29th of the current year.
HALO Trading at -3.59% from the 50-Day Moving Average
After a stumble in the market that brought HALO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -14.24% of loss for the given period.
Volatility was left at 3.10%, however, over the last 30 days, the volatility rate increased by 3.71%, as shares sank -9.59% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +6.95% upper at present.
During the last 5 trading sessions, HALO fell by -9.25%, which changed the moving average for the period of 200-days by +40.61% in comparison to the 20-day moving average, which settled at $61.01. In addition, Halozyme Therapeutics Inc. saw 52.06% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at HALO starting from HELEN TORLEY, who proposed sale 10,000 shares at the price of $58.21 back on Sep 24 ’24. After this action, HELEN TORLEY now owns shares of Halozyme Therapeutics Inc., valued at $582,101 using the latest closing price.
LaBarre Michael J., the SVP, CHIEF TECHNICAL OFFICER of Halozyme Therapeutics Inc., sale 10,000 shares at $62.88 during a trade that took place back on Sep 17 ’24, which means that LaBarre Michael J. is holding 173,756 shares at $628,780 based on the most recent closing price.
Stock Fundamentals for HALO
Current profitability levels for the company are sitting at:
- 0.46 for the present operating margin
- 0.76 for the gross margin
The net margin for Halozyme Therapeutics Inc. stands at 0.39. The total capital return value is set at 0.22. Equity return is now at value 153.16, with 17.85 for asset returns.
Based on Halozyme Therapeutics Inc. (HALO), the company’s capital structure generated 0.84 points at debt to capital in total, while cash flow to debt ratio is standing at 0.27. The debt to equity ratio resting at 5.3. The interest coverage ratio of the stock is 21.44.
Currently, EBITDA for the company is 422.43 million with net debt to EBITDA at 2.78. When we switch over and look at the enterprise to sales, we see a ratio of 9.69. The receivables turnover for the company is 4.07for trailing twelve months and the total asset turnover is 0.44. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.41.
Conclusion
To sum up, Halozyme Therapeutics Inc. (HALO) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
